Milnacipran (Ixel)

A cyclopropanecarboxamide serotonin and norepinephrine reuptake inhibitor (SNRI) that is used in the treatment of FIBROMYALGIA.

Also Known As:

Ixel; 1-Phenyl-1-diethylaminocarbonyl-2-aminomethylcyclopropane HCl; F 2207; F-2207; Midalcipran; Milnacipran Hydrochloride; Savella; 1 Phenyl 1 diethylaminocarbonyl 2 aminomethylcyclopropane HCl; F2207; Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, cis-(+-)-

Networked: 331 relevant articles (97 outcomes, 112 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 6
        Cyclopropanes: 9
        Milnacipran: 331
        Levomilnacipran: 50

Experts

1.	Palmer, Robert H: 19 articles (06/2015 - 11/2008)
2.	Clauw, Daniel J: 13 articles (11/2021 - 10/2005)
3.	Higuchi, Hisashi: 12 articles (04/2010 - 09/2003)
4.	Yoshida, Keizo: 11 articles (07/2015 - 09/2003)
5.	Gendreau, R Michael: 10 articles (06/2013 - 10/2005)
6.	Arnold, Lesley M: 9 articles (06/2015 - 06/2010)
7.	Mease, Philip J: 9 articles (06/2014 - 10/2005)
8.	Takahashi, Hitoshi: 9 articles (01/2009 - 09/2003)
9.	Kamata, Mitsuhiro: 8 articles (03/2010 - 10/2003)
10.	Wang, Yong: 7 articles (06/2014 - 11/2008)

Related Diseases

1.	Pain (Aches) 10/20/2015 - " doses of milnacipran provided moderate levels of pain relief (at least 30% pain intensity reduction) to about 40% of participants treated, compared to 30% with placebo, giving a number needed to treat for an additional beneficial outcome (NNT) of 6 to 10 (high quality evidence). " 07/01/2012 - "The highest responder rates were found in patients with greater than four-point improvement in BDI scores (milnacipran vs. placebo: pain, 57.5% vs. 39.0%; PGIC, 60.1% vs. 38.2%; 2-measure composite, 49.0% vs. 27.9%; all p < 0.01), although significant differences between treatment groups were also found in patients with no improvement or worsening of depressive symptoms. " 11/01/2008 - "Compared with placebo, significantly greater proportions of milnacipran-treated patients were FM composite responders (100 mg/d: P = 0.01; 200 mg/d: P = 0.02) and FM pain composite responders (100 mg/d: P = 0.03; 200 mg/d: P = 0.004). " 01/01/2014 - "Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study." 04/01/2010 - "Milnacipran is an effective and safe treatment for pain and other predominant symptoms of FM. "
2.	Fibromyalgia (Fibrositis) 02/01/2008 - "Further studies are needed to evaluate the safety and efficacy of milnacipran, determine optimal dosing, confirm if beneficial effects are sustained, and clarify the drug's role relative to, and in conjunction with, other treatments for fibromyalgia." 01/01/2010 - "In adults, milnacipran was generally effective in the treatment of fibromyalgia in four well designed trials of 3 or 6 months' duration. " 01/01/2013 - "To investigate whether milnacipran is safe and effective in improving cognitive function in patients with fibromyalgia. " 08/16/2013 - "Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial." 08/01/2010 - "The clinical safety and efficacy of milnacipran 100 and 200 mg/day in individuals with fibromyalgia has been investigated in four large, randomized, double-blind, placebo-controlled studies and three long-term extension studies. "
3.	Chronic Pain 09/01/2004 - "Results of this study show milnacipran to be beneficial in patients with chronic pain. " 03/01/2010 - "Treatment with milnacipran resulted in a significant improvement of chronic pain in the orofacial region irrespective of concurrent symptoms of depression. " 07/01/2011 - "Although BMS is a chronic-pain syndrome, only one self-controlled pilot study and some case reports have reported that milnacipran is effective for the treatment of chronic pain, including that caused by BMS. " 03/01/2010 - "Efficacy of milnacipran in the treatment of chronic pain syndromes." 05/01/2012 - "Plasma levels of milnacipran and its effectiveness for the treatment of chronic pain in the orofacial region."
4.	Neuralgia (Stump Neuralgia) 10/01/2012 - "In many animal studies, intrathecal administration of milnacipran is effective in neuropathic pain management. " 05/01/2005 - "Milnacipran might be effective for suppression of neuropathic pain." 07/06/2015 - "There was no evidence to support the use of milnacipran to treat neuropathic pain conditions." 07/06/2015 - "We included randomised, double-blind studies of eight weeks' duration or longer, comparing milnacipran with placebo or another active treatment in chronic neuropathic pain. " 07/06/2015 - "Milnacipran for neuropathic pain in adults."
5.	Fatigue 05/25/2010 - "Other domains assessed during the milnacipran trials include fatigue, multidimensional functioning, mood, sleep quality, and patient-reported dyscognition. " 05/01/2013 - "Studies show that milnacipran may be effective for fibromyalgia-associated symptoms including depression and fatigue. " 06/01/2014 - "Fibromyalgia patients in the milnacipran studies had high levels of baseline fatigue. " 06/01/2014 - "The objective of this study was to analyze fatigue-related data from 3 randomized, placebo-controlled trials of milnacipran (n = 3109) in fibromyalgia patients. " 10/01/2004 - "The study evaluated the efficacy and safety of milnacipran for the treatment of pain and associated symptoms such as fatigue, depressed mood and sleep. "

Related Drugs and Biologics

1.	Duloxetine Hydrochloride (Cymbalta)
2.	Serotonin (5 Hydroxytryptamine)
3.	Norepinephrine (Noradrenaline)
4.	Serotonin and Noradrenaline Reuptake Inhibitors
5.	Pregabalin (Lyrica)
6.	Antidepressive Agents (Antidepressants)
7.	Venlafaxine Hydrochloride (Effexor)
8.	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)
9.	Fluoxetine (Prozac)
10.	Ligands

Related Therapies and Procedures

1.	Therapeutics
2.	Knee Replacement Arthroplasty (Total Knee Replacement)
3.	Drug Therapy (Chemotherapy)
4.	Ligation
5.	Duration of Therapy